EVOLUS, INC. (EOLS) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
40/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinEOLS / S&P 68.86% / 15.20% |
LoseEOLS / S&P 13.87% / 15.00% |
LoseEOLS / S&P -46.39% / 50.40% |
| 2026-Q10/3 |
LoseEOLS / S&P -38.20% / -4.33% |
LoseEOLS / S&P 9.56% / 11.30% |
LoseEOLS / S&P -23.86% / 27.70% |
| 2025-Q42/3 |
WinEOLS / S&P 8.31% / 2.65% |
WinEOLS / S&P 11.61% / 9.00% |
LoseEOLS / S&P 1.25% / 13.40% |
| 2025-Q31/3 |
LoseEOLS / S&P -33.33% / 8.12% |
WinEOLS / S&P 15.10% / 4.61% |
LoseEOLS / S&P 1.11% / 13.45% |
| 2025-Q21/3 |
LoseEOLS / S&P -23.44% / 10.94% |
WinEOLS / S&P 17.15% / 4.83% |
LoseEOLS / S&P 7.78% / 10.63% |
| 2025-Q12/3 |
WinEOLS / S&P 8.97% / -4.27% |
WinEOLS / S&P 25.38% / 4.98% |
LoseEOLS / S&P -15.38% / 10.57% |
| 2024-Q41/3 |
LoseEOLS / S&P -31.85% / 2.41% |
WinEOLS / S&P 31.76% / 5.25% |
LoseEOLS / S&P -25.93% / 6.15% |
| 2024-Q32/3 |
WinEOLS / S&P 49.31% / 5.89% |
WinEOLS / S&P 34.43% / 5.89% |
LoseEOLS / S&P -19.64% / 6.11% |
| 2024-Q21/3 |
LoseEOLS / S&P -22.50% / 4.28% |
WinEOLS / S&P 40.71% / 5.38% |
LoseEOLS / S&P -23.73% / 5.12% |
| 2024-Q12/3 |
WinEOLS / S&P 32.95% / 10.56% |
WinEOLS / S&P 40.45% / 5.71% |
LoseEOLS / S&P -18.75% / 5.59% |
| 2023-Q42/3 |
WinEOLS / S&P 15.21% / 11.69% |
WinEOLS / S&P 35.98% / 6.81% |
LoseEOLS / S&P -18.80% / 7.78% |
| 2023-Q32/3 |
WinEOLS / S&P 25.72% / -3.27% |
WinEOLS / S&P 32.30% / 7.52% |
LoseEOLS / S&P -21.68% / -5.03% |
| 2023-Q21/3 |
LoseEOLS / S&P -14.07% / 8.74% |
WinEOLS / S&P 27.35% / 9.50% |
LoseEOLS / S&P -16.90% / -8.57% |
| 2023-Q13/3 |
WinEOLS / S&P 12.65% / 7.50% |
WinEOLS / S&P 28.92% / 10.77% |
WinEOLS / S&P -2.29% / -15.69% |
| 2022-Q42/3 |
LoseEOLS / S&P -6.71% / 7.56% |
WinEOLS / S&P 49.10% / 11.88% |
WinEOLS / S&P 58.33% / -17.99% |
| 2022-Q31/3 |
LoseEOLS / S&P -30.60% / -4.88% |
WinEOLS / S&P 63.13% / 13.47% |
LoseEOLS / S&P -62.17% / -1.41% |
| 2022-Q22/3 |
WinEOLS / S&P 3.39% / -16.10% |
WinEOLS / S&P 72.90% / 13.71% |
LoseEOLS / S&P -62.33% / 11.04% |
| 2022-Q12/3 |
WinEOLS / S&P 72.35% / -4.60% |
WinEOLS / S&P 108.18% / 15.97% |
LoseEOLS / S&P -67.97% / 42.23% |
| 2021-Q41/3 |
LoseEOLS / S&P -14.57% / 11.03% |
WinEOLS / S&P 76.29% / 15.00% |
LoseEOLS / S&P -82.64% / 96.40% |
| 2021-Q31/3 |
LoseEOLS / S&P -39.76% / 0.58% |
WinEOLS / S&P 54.47% / 10.77% |
LoseEOLS / S&P EOLS unavailable / 69.42% |
| 2021-Q21/3 |
LoseEOLS / S&P -2.62% / 8.55% |
WinEOLS / S&P 50.40% / 6.58% |
LoseEOLS / S&P EOLS unavailable / 51.81% |
| 2021-Q12/3 |
WinEOLS / S&P 286.61% / 6.17% |
WinEOLS / S&P 28.32% / -1.06% |
LoseEOLS / S&P EOLS unavailable / 7.39% |
| 2020-Q41/3 |
LoseEOLS / S&P -14.07% / 12.15% |
WinEOLS / S&P 61.89% / -3.72% |
LoseEOLS / S&P EOLS unavailable / -33.42% |
| 2020-Q31/3 |
LoseEOLS / S&P -26.23% / 8.93% |
WinEOLS / S&P 257.99% / -2.04% |
LoseEOLS / S&P EOLS unavailable / -27.10% |
| 2020-Q22/3 |
WinEOLS / S&P 27.71% / 20.54% |
WinEOLS / S&P 2103.20% / -0.46% |
LoseEOLS / S&P EOLS unavailable / -27.11% |
| 2020-Q10/3 |
LoseEOLS / S&P -65.90% / -19.60% |
LoseEOLS / S&P EOLS unavailable / 3.47% |
LoseEOLS / S&P EOLS unavailable / -14.75% |
| 2019-Q40/3 |
LoseEOLS / S&P -22.09% / 9.07% |
LoseEOLS / S&P EOLS unavailable / 5.36% |
LoseEOLS / S&P EOLS unavailable / 2.99% |
| 2019-Q31/3 |
WinEOLS / S&P 6.84% / 1.70% |
LoseEOLS / S&P EOLS unavailable / 5.02% |
LoseEOLS / S&P EOLS unavailable / 0.21% |
| 2019-Q20/3 |
LoseEOLS / S&P -35.22% / 4.30% |
LoseEOLS / S&P EOLS unavailable / 6.64% |
LoseEOLS / S&P EOLS unavailable / 8.65% |
| 2019-Q11/3 |
WinEOLS / S&P 89.66% / 13.65% |
LoseEOLS / S&P EOLS unavailable / 8.12% |
LoseEOLS / S&P EOLS unavailable / 14.29% |
| 2018-Q40/3 |
LoseEOLS / S&P -36.09% / -13.52% |
LoseEOLS / S&P EOLS unavailable / 9.05% |
LoseEOLS / S&P EOLS unavailable / 18.23% |
| 2018-Q30/3 |
LoseEOLS / S&P -33.48% / 7.71% |
LoseEOLS / S&P EOLS unavailable / 10.21% |
LoseEOLS / S&P EOLS unavailable / 19.06% |
| 2018-Q21/3 |
WinEOLS / S&P 209.97% / 3.43% |
LoseEOLS / S&P EOLS unavailable / 9.03% |
LoseEOLS / S&P EOLS unavailable / 14.46% |
| 2018-Q10/3 |
LoseEOLS / S&P EOLS unavailable / -0.76% |
LoseEOLS / S&P EOLS unavailable / 7.68% |
LoseEOLS / S&P EOLS unavailable / 12.46% |
| 2017-Q40/3 |
LoseEOLS / S&P EOLS unavailable / 6.64% |
LoseEOLS / S&P EOLS unavailable / 7.03% |
LoseEOLS / S&P EOLS unavailable / 13.82% |
| 2017-Q30/3 |
LoseEOLS / S&P EOLS unavailable / 4.48% |
LoseEOLS / S&P EOLS unavailable / 5.68% |
LoseEOLS / S&P EOLS unavailable / 17.57% |
| 2017-Q20/3 |
LoseEOLS / S&P EOLS unavailable / 3.09% |
LoseEOLS / S&P EOLS unavailable / 4.83% |
LoseEOLS / S&P EOLS unavailable / 17.74% |
| 2017-Q10/3 |
LoseEOLS / S&P EOLS unavailable / 6.07% |
LoseEOLS / S&P EOLS unavailable / 3.67% |
LoseEOLS / S&P EOLS unavailable / 13.32% |
| 2016-Q40/3 |
LoseEOLS / S&P EOLS unavailable / 3.82% |
LoseEOLS / S&P EOLS unavailable / 2.09% |
LoseEOLS / S&P EOLS unavailable / 7.05% |
| 2016-Q30/3 |
LoseEOLS / S&P EOLS unavailable / 3.85% |
LoseEOLS / S&P EOLS unavailable / 0.20% |
LoseEOLS / S&P EOLS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | EOLS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 16.38% | 20.78% |
| Annualized return | 16.38% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | EOLS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -14.04% | 83.14% |
| Annualized return | -2.98% | 12.86% |
10Y · 2018-02-08 to 2026-08-27
| Metric | EOLS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -22.78% | 319.30% |
| Annualized return | -2.55% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |